Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

  • Revenue in CNY (TTM)19.72bn
  • Net income in CNY-6.18bn
  • Incorporated2010
  • Employees10.47k
  • Location
    Beigene Ltd94 Solaris Avenue,, Camana BayGRAND CAYMAN KY1-1108Cayman IslandsCYM
  • Phone+1 3 459494123
  • Websitehttps://www.beigene.com/
More ▼

Institutional shareholders

19.67%Per cent of shares held by top holders
HolderShares% Held
Penghua Fund Management Co., Ltd.as of 31 Dec 20235.04m4.38%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 20234.22m3.67%
Taiping Life Insurance Co. Ltd. (Investment Portfolio)as of 15 Dec 20222.41m2.09%
Abu Dhabi Investment Authority (Investment Management)as of 15 Dec 20222.41m2.09%
China International Capital Corp. Ltd. (Invt Management)as of 15 Dec 20222.07m1.80%
Bank of China Investment Management Co., Ltd.as of 31 Dec 20231.62m1.41%
China Fund Management Co., Ltd.as of 31 Dec 20231.38m1.20%
China Universal Asset Management Co., Ltd.as of 31 Dec 20231.21m1.05%
GF Fund Management Co., Ltd.as of 31 Dec 20231.20m1.04%
Wanjia Asset Management Co., Ltd.as of 31 Dec 20231.08m0.94%
More ▼
Data from 30 Jun 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.